Geron (GERN) Competitors $1.60 -0.02 (-1.23%) Closing price 04:00 PM EasternExtended Trading$1.59 -0.01 (-0.63%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GERN vs. BCRX, LGND, FOLD, CLDX, MNKD, INVA, DVAX, NVAX, OPK, and RGLSShould you be buying Geron stock or one of its competitors? The main competitors of Geron include BioCryst Pharmaceuticals (BCRX), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), Innoviva (INVA), Dynavax Technologies (DVAX), Novavax (NVAX), OPKO Health (OPK), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. Geron vs. BioCryst Pharmaceuticals Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics MannKind Innoviva Dynavax Technologies Novavax OPKO Health Regulus Therapeutics BioCryst Pharmaceuticals (NASDAQ:BCRX) and Geron (NASDAQ:GERN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings, analyst recommendations and community ranking. Which has preferable earnings and valuation, BCRX or GERN? Geron has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCryst Pharmaceuticals$503.49M4.58-$226.54M-$0.26-42.35Geron$116.29M8.76-$184.13M-$0.21-7.62 Do insiders & institutionals believe in BCRX or GERN? 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 7.4% of Geron shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate BCRX or GERN? BioCryst Pharmaceuticals currently has a consensus price target of $16.56, suggesting a potential upside of 50.37%. Geron has a consensus price target of $5.06, suggesting a potential upside of 216.41%. Given Geron's higher probable upside, analysts clearly believe Geron is more favorable than BioCryst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Geron 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.78 Does the media prefer BCRX or GERN? In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Geron. MarketBeat recorded 6 mentions for BioCryst Pharmaceuticals and 4 mentions for Geron. Geron's average media sentiment score of 1.00 beat BioCryst Pharmaceuticals' score of 0.91 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BCRX or GERN more profitable? BioCryst Pharmaceuticals has a net margin of -30.01% compared to Geron's net margin of -682.48%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets BioCryst Pharmaceuticals-30.01% N/A -24.06% Geron -682.48%-67.53%-45.46% Does the MarketBeat Community prefer BCRX or GERN? Geron received 1 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. Likewise, 69.93% of users gave Geron an outperform vote while only 67.16% of users gave BioCryst Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBioCryst PharmaceuticalsOutperform Votes49967.16% Underperform Votes24432.84% GeronOutperform Votes50069.93% Underperform Votes21530.07% Which has more risk and volatility, BCRX or GERN? BioCryst Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. SummaryGeron beats BioCryst Pharmaceuticals on 10 of the 19 factors compared between the two stocks. Get Geron News Delivered to You Automatically Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GERN vs. The Competition Export to ExcelMetricGeronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$6.83B$5.57B$8.67BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-5.008.8327.3320.19Price / Sales8.76263.63412.94162.04Price / CashN/A65.8538.2534.64Price / Book3.486.677.114.72Net Income-$184.13M$143.49M$3.23B$247.80M7 Day Performance1.91%6.30%4.31%3.36%1 Month Performance35.02%15.37%13.02%9.70%1 Year Performance-68.25%6.72%31.36%14.41% Geron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GERNGeron3.1032 of 5 stars$1.60-1.2%$5.06+216.4%-64.7%$1.02B$116.29M-5.0070BCRXBioCryst Pharmaceuticals4.3591 of 5 stars$10.73-0.2%$16.56+54.3%+76.1%$2.25B$503.49M-17.59530Analyst RevisionLGNDLigand Pharmaceuticals4.8205 of 5 stars$101.64-0.5%$146.14+43.8%+34.6%$1.96B$181.49M40.4980Positive NewsFOLDAmicus Therapeutics3.7199 of 5 stars$6.16+1.5%$16.22+163.3%-40.0%$1.90B$543.14M-34.22480CLDXCelldex Therapeutics1.9813 of 5 stars$19.97+1.0%$53.90+169.9%-41.3%$1.33B$7.56M-7.77150Positive NewsAnalyst RevisionMNKDMannKind3.0284 of 5 stars$4.29+3.4%$10.00+133.1%-6.4%$1.30B$297.60M61.29400Trending NewsAnalyst RevisionGap DownINVAInnoviva4.3992 of 5 stars$20.14+2.9%$55.00+173.1%+33.7%$1.26B$369.84M29.19100News CoverageHigh Trading VolumeDVAXDynavax Technologies4.4714 of 5 stars$9.84+0.5%$24.00+143.9%-14.8%$1.18B$294.62M54.67350News CoverageNVAXNovavax3.8192 of 5 stars$7.07-3.7%$19.00+168.7%-59.2%$1.15B$1.21B-3.131,990Positive NewsOPKOPKO Health4.528 of 5 stars$1.38+1.5%$2.75+99.3%+7.0%$1.09B$689.41M-7.264,200Positive NewsRGLSRegulus Therapeutics2.2796 of 5 stars$7.94+0.1%$8.50+7.1%+272.2%$549.72MN/A-7.4230Positive News Related Companies and Tools Related Companies BCRX Competitors LGND Competitors FOLD Competitors CLDX Competitors MNKD Competitors INVA Competitors DVAX Competitors NVAX Competitors OPK Competitors RGLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GERN) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
